CDKN2A Antibodies

The alternative splicing in the first exon of the CDKN2A (cyclin-dependent kinase inhibitor 2A, which is also known as P16 or p16Ink4A) gene results in several transcript variants. At least two of these isoforms inhibit CDK4 kinase. The human CD2A1 variant interacts with CDK4 and CDK6 to negatively regulate cell proliferation, which prevents CDK4 and CDK6 from interacting with cyclin D and phosphorylating the retinoblastoma protein. The alternate reading frame of CDKN2A, p14ARF, stabilizes the tumor suppressor protein p53 by sequestering MDM1, which degrades p53. Additionally, the human CD2A2 variant can induce the arrest of the cell cycle in G1 and G2 phases. Mutations in CDKN2A are correlated with an increased risk of cancer. Malignant melanoma type 2 (CMM2), familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC), Li-Fraumeni syndrome (LFS) and melanoma-astrocytoma syndrome (MASTS) are diseases associated with mutations in CDKN2A. CDKN2A has been studied as a prognostic marker for several types of cancer.

Explore the Cell Cycle: G2/M DNA Damage Checkpoint Regulation Interactive Pathway
Explore the Cell Cycle: G2/M DNA Damage Checkpoint Regulation Interactive Pathway

Product #

Description

Form

Gene Symbol (ID)

Species Reactivity

Application

Add to Cart

GW21185 Anti-CDKN2A antibody produced in chicken affinity isolated antibody
human ... CDKN2A(1029)
rat, mouse, human
WB
SAB2500221 Anti-CDKN2A (Isoform 1)/P16INK4A antibody produced in goat affinity isolated antibody
human ... CDKN2A(1029)
human
ELISA (i), IHC, WB
SAB4500073 Anti-p14 ARF antibody produced in rabbit affinity isolated antibody
human ... CDKN2A(1029)
human
ELISA, IF, IHC, WB
P2610 Monoclonal Anti-p14ARF antibody produced in mouse purified immunoglobulin
human ... CDKN2A(1029)
human
ARR, IHC (p), WB
SAB4500072 Anti-p16 INK, N-Terminal antibody produced in rabbit affinity isolated antibody
human ... CDKN2A(1029)
human, mouse
ELISA, WB